Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-027 Katowice, Poland.
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Medicina (Kaunas). 2022 Jan 19;58(2):153. doi: 10.3390/medicina58020153.
Soluble cell adhesion molecules (sCAMs) play a significant role in the metastatic potential of breast cancer (BC). They might block lymphocytes and promote angiogenesis and migration of cancer cells. We assessed the usefulness of sCAMs in the prognosis and monitoring of the progression of advanced BC. We assessed soluble E-selectin, P-selectin, VCAM-1, ICAM-1, EpCAM, IL-6Ra, TNF-R1, and TNF-R2 in 39 women with aBC. Blood samples were obtained at the beginning of the treatment and after 2 months. The median progression-free survival (PFS) was 9 months, and overall survival (OS) was 27 months. The higher levels of sICAM-1 (HR = 2.60, = 0.06) and lower levels of sEpCAM (HR = 2.72, < 0.05) were associated with faster progression of aBC. High levels of sEpCAM through the follow-up period were significantly associated with a lower risk of progression (HR = 0.40, < 0.01). We found the independent predictive value of higher than median sICAM-1 levels for PFS (HR = 2.07, = 0.08) and of sVCAM-1 levels for OS (HR = 2.59, < 0.05). Our data support the predictive value of sICAM-1 and sVCAM-1 and suggest that they could become markers for tailoring new therapies in aBC. sEpCAM level could be used as an early indicator of response to the therapy.
可溶性细胞黏附分子 (sCAMs) 在乳腺癌 (BC) 的转移潜能中发挥重要作用。它们可能阻止淋巴细胞并促进癌细胞的血管生成和迁移。我们评估了 sCAMs 在预测和监测晚期 BC 进展中的作用。我们评估了 39 名 aBC 女性的可溶性 E-选择素、P-选择素、VCAM-1、ICAM-1、EpCAM、IL-6Ra、TNF-R1 和 TNF-R2。在治疗开始时和 2 个月后采集血样。中位无进展生存期 (PFS) 为 9 个月，总生存期 (OS) 为 27 个月。较高水平的 sICAM-1 (HR = 2.60, = 0.06) 和较低水平的 sEpCAM (HR = 2.72, < 0.05) 与 aBC 的快速进展相关。在随访期间，较高水平的 sEpCAM 与较低的进展风险显著相关 (HR = 0.40, < 0.01)。我们发现高于中位数的 sICAM-1 水平对 PFS 的独立预测价值 (HR = 2.07, = 0.08) 和 sVCAM-1 水平对 OS 的独立预测价值 (HR = 2.59, < 0.05)。我们的数据支持 sICAM-1 和 sVCAM-1 的预测价值，并表明它们可能成为定制 aBC 新疗法的标志物。sEpCAM 水平可作为治疗反应的早期指标。
